GlassScriptPhysician profile
Rashmi Chandra
NPI 1437304847
$2,805.49
in general payments reported to CMS, 2019-2025
25 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $336 · 2021: $43.50 · 2022: $252 · 2023: $639 · 2024: $536 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.31 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $443.49 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $227.81 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $203.54 | 2023-2025 | |
| Vifor Pharma, INC. | $191.86 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $182.90 | 2022-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $173.29 | 2019-2023 | Korsuva, Velphoro |
| Glaxosmithkline, LLC. | $168.90 | 2023-2025 | Benlysta, Jesduvroq, Shingrix |
| Mallinckrodt Enterprises LLC | $152.88 | 2019 | |
| Amgen INC. | $145.30 | 2023-2025 | Tavneos, Parsabiv, Aranesp |
| Veloxis Pharmaceuticals, INC. | $124.25 | 2020 | |
| Opko Pharmaceuticals, LLC | $94.06 | 2023-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $77.14 | 2019-2025 | |
| Baxter Healthcare | $67.82 | 2020 | |
| Ani Pharmaceuticals, INC. | $64.09 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $60.00 | 2023-2024 | Ozempic, Rybelsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $56.04 | 2022-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $55.63 | 2023-2025 | |
| Ardelyx, INC. | $53.93 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $50.27 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $47.96 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.93 | 2023-2025 | Jardiance |
| Shire North American Group INC | $43.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.33 | 2019 | |
| Akebia Therapeutics INC | $22.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.